Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Recommendation of “Buy” by Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has been given a consensus recommendation of “Buy” by the ten analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $8.50.

AQST has been the topic of a number of recent research reports. Lake Street Capital set a $6.00 price objective on shares of Aquestive Therapeutics in a research note on Tuesday, February 3rd. Piper Sandler upped their target price on Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Wall Street Zen downgraded Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of large investors have recently made changes to their positions in the business. Voloridge Investment Management LLC acquired a new stake in shares of Aquestive Therapeutics in the 4th quarter worth $1,254,000. Numerai GP LLC acquired a new position in Aquestive Therapeutics during the 4th quarter valued at about $789,000. Occudo Quantitative Strategies LP acquired a new position in Aquestive Therapeutics during the 4th quarter valued at about $365,000. Millennium Management LLC raised its stake in Aquestive Therapeutics by 19.1% in the fourth quarter. Millennium Management LLC now owns 1,535,369 shares of the company’s stock valued at $9,918,000 after buying an additional 246,040 shares during the last quarter. Finally, Man Group plc acquired a new stake in Aquestive Therapeutics in the fourth quarter worth about $189,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Price Performance

AQST stock opened at $3.83 on Thursday. Aquestive Therapeutics has a 1-year low of $2.12 and a 1-year high of $7.55. The business has a 50-day moving average price of $4.65 and a 200 day moving average price of $5.19. The company has a market capitalization of $467.26 million, a P/E ratio of -5.39 and a beta of 1.65.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.